Literature DB >> 26003341

Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists.

Joren Guillaume1, Nora Pauwels1, Sandrine Aspeslagh2, Dirk M Zajonc3, Dirk Elewaut4, Serge Van Calenbergh5.   

Abstract

Alpha-galactosyl ceramide (α-GalCer) is a prototypical synthetic ligand of invariant natural killer T (iNKT) cells. Upon presentation by the MHC class I-like molecule CD1d, this glycolipid stimulates iNKT cells to secrete a vast amount of both pro-inflammatory Th1 and anti-inflammatory Th2 cytokines. Recently, we discovered that selected 6″-modified α-GalCer analogues may produce markedly Th1-biased responses due to the formation of either an additional anchor with CD1d or by establishing extra interactions with the T-cell receptor of iNKT cells. Here, we report a practical synthesis towards 6″-O-carbamate and galacturonamide analogues of α-GalCer and their evaluation as iNKT cell agonists in mice.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD1d; Glycolipids; iNKT-cells; α-GalCer

Mesh:

Substances:

Year:  2015        PMID: 26003341      PMCID: PMC4461518          DOI: 10.1016/j.bmc.2015.04.068

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  20 in total

1.  Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor.

Authors:  Dirk M Zajonc; Carlos Cantu; Jochen Mattner; Dapeng Zhou; Paul B Savage; Albert Bendelac; Ian A Wilson; Luc Teyton
Journal:  Nat Immunol       Date:  2005-07-10       Impact factor: 25.606

2.  Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population.

Authors:  Jonathan M Coquet; Sumone Chakravarti; Konstantinos Kyparissoudis; Finlay W McNab; Lauren A Pitt; Brent S McKenzie; Stuart P Berzins; Mark J Smyth; Dale I Godfrey
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-06       Impact factor: 11.205

3.  6'-derivatised alpha-GalCer analogues capable of inducing strong CD1d-mediated Th1-biased NKT cell responses in mice.

Authors:  Matthias Trappeniers; Katrien Van Beneden; Tine Decruy; Ulrik Hillaert; Bruno Linclau; Dirk Elewaut; Serge Van Calenbergh
Journal:  J Am Chem Soc       Date:  2008-12-10       Impact factor: 15.419

4.  Synthesis of 6"-triazole-substituted α-GalCer analogues as potent iNKT cell stimulating ligands.

Authors:  Nora Pauwels; Sandrine Aspeslagh; Dirk Elewaut; Serge Van Calenbergh
Journal:  Bioorg Med Chem       Date:  2012-10-12       Impact factor: 3.641

5.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.

Authors:  T Kawano; J Cui; Y Koezuka; I Toura; Y Kaneko; K Motoki; H Ueno; R Nakagawa; H Sato; E Kondo; H Koseki; M Taniguchi
Journal:  Science       Date:  1997-11-28       Impact factor: 47.728

6.  Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.

Authors:  Xiangming Li; Masakazu Fujio; Masakazu Imamura; Douglass Wu; Sandhya Vasan; Chi-Huey Wong; David D Ho; Moriya Tsuji
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-02       Impact factor: 11.205

Review 7.  The stimulating adventure of KRN 7000.

Authors:  Aline Banchet-Cadeddu; Eric Hénon; Manuel Dauchez; Jean-Hugues Renault; Fanny Monneaux; Arnaud Haudrechy
Journal:  Org Biomol Chem       Date:  2011-03-11       Impact factor: 3.876

8.  A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.

Authors:  Aki Ishikawa; Shinichiro Motohashi; Eiichi Ishikawa; Hiroki Fuchida; Kazuko Higashino; Mizuto Otsuji; Toshihiko Iizasa; Toshinori Nakayama; Masaru Taniguchi; Takehiko Fujisawa
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

9.  Enhanced TCR footprint by a novel glycolipid increases NKT-dependent tumor protection.

Authors:  Sandrine Aspeslagh; Marek Nemčovič; Nora Pauwels; Koen Venken; Jing Wang; Serge Van Calenbergh; Dirk M Zajonc; Dirk Elewaut
Journal:  J Immunol       Date:  2013-08-19       Impact factor: 5.422

10.  A multifactorial mechanism in the superior antimalarial activity of alpha-C-GalCer.

Authors:  John Schmieg; Guangli Yang; Richard W Franck; Moriya Tsuji
Journal:  J Biomed Biotechnol       Date:  2009-12-27
View more
  5 in total

1.  4"-O-Alkylated α-Galactosylceramide Analogues as iNKT-Cell Antigens: Synthetic, Biological, and Structural Studies.

Authors:  Jonas Janssens; Aruna Bitra; Jing Wang; Tine Decruy; Koen Venken; Johan van der Eycken; Dirk Elewaut; Dirk M Zajonc; Serge van Calenbergh
Journal:  ChemMedChem       Date:  2018-12-17       Impact factor: 3.466

Review 2.  Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.

Authors:  Mary Speir; Ian F Hermans; Robert Weinkove
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

3.  6″-Modifed α-GalCer-peptide conjugate vaccine candidates protect against liver-stage malaria.

Authors:  Michael A Meijlink; Yu Cheng Chua; Susanna T S Chan; Regan J Anderson; Matthew W Rosenberg; Anton Cozijnsen; Vanessa Mollard; Geoffrey I McFadden; Sarah L Draper; Lauren E Holz; Ian F Hermans; William R Heath; Gavin F Painter; Benjamin J Compton
Journal:  RSC Chem Biol       Date:  2022-03-02

4.  Efficient Divergent Synthesis of New Immunostimulant 4″-Modified α-Galactosylceramide Analogues.

Authors:  Jonas Janssens; Tine Decruy; Koen Venken; Toshiyuki Seki; Simon Krols; Johan Van der Eycken; Moriya Tsuji; Dirk Elewaut; Serge Van Calenbergh
Journal:  ACS Med Chem Lett       Date:  2017-05-05       Impact factor: 4.345

5.  Synthesis and structure-activity relationships of cerebroside analogues as substrates of cerebroside sulphotransferase and discovery of a competitive inhibitor.

Authors:  Wenjin Li; Joren Guillaume; Younis Baqi; Isabell Wachsmann; Volkmar Gieselmann; Serge Van Calenbergh; Christa E Müller
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.